N4 Pharma plc
N4 Pharma (N4P) has released a further, highly encouraging update from its ongoing in vitro siRNA research work. This demonstrates a strong beneficial effect on cellular inhibition from combined loading of EGFR (epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) onto the same Nuvec® nanoparticle, compared to single-dose siRNA when tested in PC9 lung cancer cells. The effect was seen to increase over time up to 48 hours in a number of repeat experiments, heightening each time according to the amount of siRNA applied. This news of course closely follows the Group’s 7 December 2023 release that also confirmed Nuvec® ’s ability to be loaded with and concurrently deliver two (or more) different siRNA known to inhibit relevant oncology targets without changes to size or charge, which are two essential parameters for successful cellular uptake. Taken together, these results suggest forthcoming clinical validation could rapidly elevate Nuvec® and/or the Group’s LipTide® platform (which was recently secured through its Nanogenics Limited acquisition) into potentially lucrative third-party licensing/partnering opportunities. With the Group presently retaining a cash runway that extends into H2 2024 and with further works exploring siRNA concentrations/dose loading/oral bioavailability across different cell lines shortly underway, along with new in vivo studies and possibly further updates covering N4P’s ongoing AAV viral vector testing, the coming months look to be a particularly busy period.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to N4 Pharma plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.